Serology to COVID-19 for Recording Exposures and Evaluating Needs (SCREEN)

Cincinnati Children's Hospital Medical Center logo

Cincinnati Children's Hospital Medical Center

Status

Terminated

Conditions

SARS-CoV Infection
Covid19
Coronavirus

Treatments

Diagnostic Test: SARS-CoV-2

Study type

Observational

Funder types

Other

Identifiers

NCT04566965
SCREEN

Details and patient eligibility

About

As the global and pandemic spread of the novel coronavirus (SARS-CoV-2, COVID-19) continues, many knowledge gaps remain with regard to the epidemiology and transmission of infection, as well as the normal immunological responses after viral exposure. Cincinnati had its first confirmed case of COVID-19 on March 14, 2020, and despite extensive shelter-in-place and social distancing efforts, community spread continues at over 150-200 new cases per week. As new residents and fellows arrive in July 2020 to Cincinnati Children's Hospital Medical Center (CCHMC), many of whom come from metropolitan areas across the country, it is imperative that investigators determine the current prevalence of infection, measure the cumulative incidence of infection over the next 12-24 months, investigate the normal antibody patterns after infection, and help elucidate what constitutes a protective immunological response. The investigators have a unique but time-limited opportunity to optimally track the epidemiology and natural history of SARS-CoV-2 infection among trainees at CCHMC, including risk factors for transmission and immunological recovery. SCREEN will investigate epidemiological and immunological features of SARS-CoV-2 virus infection within the cohort of CCHMC residents and fellows who have patient contact. By collecting and analyzing weekly serial samples for SARS-CoV-2 (nasal swab for virus by PCR) and monthly serological exposure (serum antibodies by ELISA), the investigators will determine the prevalence and cumulative incidence of infection by SARS-CoV-2; the investigators will also document the antibody responses over time and identify cases of apparent viral recrudescence or re-infection.

Enrollment

232 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Current full-time residents and fellows at CCHMC
  • Cell phone that can be used for text messaging or web-based viewing of surveys
  • Willing and able to provide informed consent
  • Ability to comply with all study related evaluations and follow-up

Exclusion criteria

Any condition or illness that makes study participation ill-advised

Trial design

232 participants in 1 patient group

Full-Time CCHMC Employees
Description:
All CCHMC full-time residents and fellows who have some direct contact with patients and their families as part of normal workplace duties.
Treatment:
Diagnostic Test: SARS-CoV-2

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems